EN | RU
EN | RU

Help Support

Back

Post hoc analysis evaluates onset of symptomatic response with vedolizumab in ulcerative colitis patients

Post hoc analysis evaluates onset of symptomatic response with vedolizumab in ulcerative colitis patients Post hoc analysis evaluates onset of symptomatic response with vedolizumab in ulcerative colitis patients
Post hoc analysis evaluates onset of symptomatic response with vedolizumab in ulcerative colitis patients Post hoc analysis evaluates onset of symptomatic response with vedolizumab in ulcerative colitis patients

A study was carried to determine the onset of symptomatic response with vedolizumab in individuals suffering from moderate-to-severe ulcerative colitis.

See All

Key take away

Vedolizumab leads to a rapid symptomatic response, specifically in anti-tumor necrosis factor (TNFα)-naive ulcerative colitis patients, Early symptomatic improvement predicts the therapeutic response at week 10.

Background

A study was carried to determine the onset of symptomatic response with vedolizumab in individuals suffering from moderate-to-severe ulcerative colitis.

Method

In this post hoc analysis of a randomized, placebo-controlled phase III trial, participants were randomly assigned to receive vedolizumab 300 mg (n = 164) or placebo (n = 82) at weeks 0, two, and six. Mayo subscores were assessed in individuals having baseline stool frequency ≥1 and rectal bleeding ≥1. In subjects having baseline stool frequency ≥2 and rectal bleeding ≥1, the percentage attaining stool frequency ≤1 and rectal bleeding = 0 was assessed.

Result

From week two, the decline in mean stool frequency subscore from baseline was higher with vedolizumab compared to placebo (-6.6%), with a higher difference in anti-TNF α-naive patients (vedolizumab vs. placebo, -13.2%). From the sixth week, the mean percentage decline from baseline rectal bleeding subscore was numerically higher with vedolizumab compared to placebo in anti-TNFα-naive subjects (-10.7%).

More individuals in the anti-TNFα-naive subgroup attained stool frequency ≤1 and rectal bleeding = 0 with vedolizumab compared to placebo at week 2 (14.8%) and week 6 (20.3%). Individuals having stool frequency ≤1 and rectal bleeding = 0 at week two had greater clinical  remission and response, and mucosal healing rates at week 10 in comparison with the devoid subjects.

Conclusion

In anti-TNFα-naive ulcerative colitis patients, vedolizumab induces a prompt symptomatic response.

Source:

Digestion

Article:

Week 2 Symptomatic Response with Vedolizumab as a Predictive Factor in Japanese Anti-TNFα-Naive Patients with Ulcerative Colitis: A post hoc Analysis of a Randomized, Placebo-Controlled Phase 3 Trial

Authors:

Masakazu Nagahori et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: